Skip to content
2000
Volume 15, Issue 29
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Metabolic syndrome (MetS) is a cluster of risk factors, each one individually associated with increased cardiovascular disease risk. Treatment of all components of MetS is expected to result in reduced risk. Treatment of MetS mainly includes lifestyle changes. In addition, drug therapy may be considered, especially combinations of different drugs, in order to tackle all the features of MetS. We review the therapeutic strategies currently used for obesity and dyslipidemia treatment in patients with MetS, with a focus on drug combinations.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/138161209789105054
2009-10-01
2025-12-08
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/138161209789105054
Loading

  • Article Type:
    Research Article
Keyword(s): Bile acid sequestrants; ezetimibe; fibrates; metabolic syndrome; niacin; orlistat; rimonabant; statins
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test